A locally advanced PML::JAK1 myofibroblastic sarcoma arising in the neck.

Saeko Soejima, Jotaro Nakashima, Naoki Kojima, Miyako Kitazono, Dai Inoue, Shunji Takahashi, Haruka Okada

Abstract read

In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Saeko Soejima *Department of Pathology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu-Shi, Tokyo, 183-8524, Japan. saeko_soejima@tmhp.jp.ORCID http://orcid.org/0009-0000-0122-4629

Jotaro Nakashima *Department of Pathology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu-Shi, Tokyo, 183-8524, Japan.

Naoki KojimaDepartment of Pathology, Saitama Cancer Center, Kitaadachi-Gun, Saitama, Japan.

Miyako KitazonoDepartment of Respiratory Medicine and Oncology, Tokyo Metropolitan Tama Medical Center, Fuchu-Shi, Tokyo, Japan.

Dai InoueDepartment of Clinical Genetics, Tokyo Metropolitan Tama Medical Center, Fuchu-Shi, Tokyo, Japan.

Shunji TakahashiDepartment of Genomic Medicine, Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-Ku, Tokyo, Japan.

Haruka OkadaDepartment of Pathology, Tokyo Metropolitan Tama Medical Center, 2-8-29 Musashidai, Fuchu-Shi, Tokyo, 183-8524, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 54-year-old male patient presented with a painful right cervical mass encasing the common carotid artery. Histologically, the tumor consisted of polygonal to spindle-shaped cells with mild nuclear atypia and low mitotic activity (0-1/10 high-power fields). No myxoid stroma or necrosis was identified, and desmin expression was patchy. GenMineTOP, a dual DNA-RNA comprehensive genomic profiling system, revealed a PML exon 7-JAK1 exon 5 fusion. The tumor was surgically unresectable because of circumferential encasement of the right common carotid artery. After radiotherapy followed by doxorubicin chemotherapy, no distant metastases developed during 17 months of follow-up. PML::JAK1 myofibroblastic sarcomas have previously been reported in four abdominal cases, most of which showed aggressive behavior. This cervical case broadens the anatomic spectrum of PML::JAK1 myofibroblastic sarcomas to include the head and neck region and further expands their morphologic spectrum.

Indexed as

Cervical sarcomaJAK-STAT signalingLocally advanced sarcomaMyofibroblastic differentiationNext-generation sequencingPML::JAK1 Fusion

Identifiers

PMID42900368

DOI10.1016/S1470-2045(23)00589-2

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.